Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P+CIOD versus CVTLP induction therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia
ChiCTR1900023805Phase 4Not yet recruiting
- Sponsor
- Medical Center of Hematology, Xinqiao Hospital, Army Medical University
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegaspargase, cyclophosphamide, idarubicin, daunorubicin, vindesine and 1 more in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Medical Center of Hematology, Xinqiao Hospital, Army Medical University. Primary endpoint: Rate of minimal residual disease negativity. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
pegaspargasecyclophosphamideidarubicindaunorubicinvindesine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR1900023805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023805.